AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

FDA announced a new pilot program designed to provide faster reviews for domestically tested and manufactured generic drugs.

Rocket ditches blood disorder gene therapy in ongoing pipeline pivot

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting